Bobbi Conner talks with MUSC's Dr. Thomas Curran about the latest research showing that a structured exercise program extends ...

The Medical University of South Carolina (MUSC) Hollings Cancer Center, US, has enrolled the first subject in the Phase II/III FORTIFI-NH01 trial of ficerafusp alfa to treat individuals with human ...

FLORENCE (February 3, 2025)– MUSC Health Florence Medical Center announces a new innovative addition to MUSC Hollings Cancer Center, the only NCI-designated cancer center in South Carolina.

The MUSC Hollings Cancer Center received an $8.9 million grant from the NCI designed to foster collaboration across clinical and laboratory research for the study of signaling in sphingolipids, a ...

MUSC Hollings Cancer Center researcher Sophie Paczesny, M.D., Ph.D., recently received a four-year grant from the National Heart, Lung, and Blood Institute to investigate solutions to help doctors ...

CHARLESTON, S.C. (WCIV) — The MUSC Hollings Cancer Center launches a next-day appointment access program for patients diagnosed with abdominal cancer. The new program is built for patients ...

MUSC Hollings Cancer Center-Orangeburg Clinical Director Dr. Chris Y. Brunson said, “We’ve made a lot of headway taking care of patients here. My expectation is that services for the community ...

MUSC Hollings Cancer Center is a significant driver of the South Carolina economy, according to a new study authored by Joey Von Nessen, Ph.D., a research economist at the University of South ...

LOWCOUNTRY, S.C. (WCIV) — A new study from the MUSC Hollings Cancer Center has shown a potential connection between the HPV vaccination and cervical cancer deaths. In their study they noted that ...

The Orangeburg hospital’s alignment with the Hollings Cancer Center expands access to innovative treatment options, trailblazing research and unparalleled expertise, MUSC said in a press release.

Caption: MUSC Hollings Cancer Center pioneers new drug for Triple-negative Breast Cancer treatment (WCIV) New research out of Dr. Sahin’s lab may be the answer certain patients are searching for.

The Medical University of South Carolina (MUSC) Hollings Cancer Center, US, has enrolled the first subject in the Phase II/III FORTIFI-NH01 trial of ficerafusp alfa to treat individuals with human ...